Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

OncoCyte Corp

0KCC
Current price
2.92 USD -0.22 USD (-7.01%)
Last closed 3.08 USD
ISIN US68235C1071
Sector Healthcare
Industry Diagnostics & Research
Exchange London Exchange
Capitalization 41 174 672 USD
Yield for 12 month -6.39 %
1Y
3Y
5Y
10Y
15Y
0KCC
21.11.2021 - 28.11.2021

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Address: 15 Cushing, Irvine, CA, United States, 92618

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.75 USD

P/E ratio

Dividend Yield

Current Year

+1 503 000 USD

Last Year

+958 000 USD

Current Quarter

+104 000 USD

Last Quarter

+176 000 USD

Current Year

+501 000 USD

Last Year

-18 000 USD

Current Quarter

-230 500 USD

Last Quarter

-335 000 USD

Key Figures 0KCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -20 222 000 USD
Operating Margin TTM -5445.19 %
PE Ratio
Return On Assets TTM -16.67 %
PEG Ratio
Return On Equity TTM -101.76 %
Wall Street Target Price 3.75 USD
Revenue TTM 1 023 000 USD
Book Value 1.7 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -77.5 %
Dividend Yield
Gross Profit TTM 188 000 USD
Earnings per share -4.28 USD
Diluted Eps TTM -4.28 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 0KCC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 0KCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 25.07.2023
Dividend Date

Stock Valuation 0KCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 34.7856
Price Sales TTM 40.2489
Enterprise Value EBITDA -1.2504
Price Book MRQ 1.8136

Financials 0KCC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0KCC

For 52 weeks

2.08 USD 4.34 USD
50 Day MA 3.13 USD
Shares Short Prior Month 203 084
200 Day MA 3 USD
Short Ratio 13.1
Shares Short 190 242
Short Percent 1.44 %